vidual variability in the expression of these enzymes, the aripiprazole concentration varies among healthy individuals after administration of the drug (5 ). In patients, insufficient response or side effects, such as somnolence, akathisia, or nausea, may result from too low or too high drug concentrations. Therapeutic drug monitoring (TDM), which is established practice for many antipsychotic drugs (6, 7 ) , may be helpful for patients treated with aripiprazole. We measured aripiprazole by HPLC with column-switching and ultraviolet detection, based on a previously reported method for TDM of the antidepressant reboxetine (8 ) .
Pure drug was not available; we therefore incubated tablets containing 15 mg of aripiprazole base (Abilify ® ; Bristol-Myers Squibb/Otsuka Pharmaceuticals) for several days in the dark at room temperature in 15 mL per tablet of methanol (LiChrosolve; Merck) or ultrapure water adjusted to pH 2 with 0.1 mol/L HCl. Before chromatographic analysis, suspensions were shaken and cleared by centrifugation (3000g for 5 min). Maximum solution was attained within the first 24 h. Because the mean drug concentrations in samples diluted to concentrations of 100, 200, or 500 g/L differed little (2.7%; range, Ϫ7% to 10%) between methanol and water solutions, complete solution by methanol was assumed. Methanolic solutions were used for the preparation of calibrator samples with 6 concentrations between 50 and 500 g/L and quality-control samples containing 50, 250, or 400 g/L, prepared by supplementing drug-free plasma with aripiprazole. Perphenazine base from Sigma was used as internal standard in a final concentration of 0.0615 g/L.
Blood for serum preparation was collected from 27 schizophrenic patients who had been treated with aripiprazole. The study protocol was approved by the local ethics committee.
HPLC was performed with an Agilent 1100 series (Bio-Rad) analyzer consisting of an autosampler, a thermostated column set at 25°C with an electric 6-port switching valve coupled to an autosampler, and 2 HPLC pumps. The variable-wavelength ultraviolet detector for monitoring absorbance was set at 210 nm. HP ChemStation software (Ver. 09.01) was used for data acquisition and integration. The analytical column [250 ϫ 4.6 mm (i. A solution of 99 L of serum mixed with 1 L of internal standard was injected automatically on the clean-up column. Interfering matrix compounds were washed to the waste with deionized water containing 80 mL/L acetonitrile at a flow rate of 0.8 mL/min for 5 min. After clean-up, the electric 6-port valve was switched, and the drug to be determined was eluted to the analytical column by a mobile phase consisting of 500 mL/L acetonitrile (LiChrosolve) in phosphate buffer [1.825 g/L dipotassium phosphate trihydrate (Merck) in deionized water and adjusted to pH 6.4 with 850 mL/L phosphoric acid (Merck)] at a flow rate of 1.2 mL/min. At 15 min, the switching valve was reset, and separation on the analytical column continued.
Peak heights were used for quantification. Calibrators and quality-control samples were measured twice a day over 5 days to evaluate interassay variability, assay linearity, and recovery. The sequence was as follows: drugfree plasma, control plasma with 250 g/L supplement, sample with 50 g/L supplement, calibration sample 1 (100 g/L), sample with 400 g/L supplement, calibration sample 2 (150 g/L), calibration sample 3 (200 g/L), sample with 400 g/L supplement, sample with 250 g/L supplement, calibration sample 4 (300 g/L), sample with 50 g/L supplement, calibration sample 5 (350 g/L), sample with 400 g/L supplement, sample with 250 g/L supplement, sample with 50 g/L supplement, and finally, calibration sample 6 (500 g/L).
Chromatographic peaks were confirmed by tandem mass spectrometry (MS/MS) (9 ) on a Micromass Quattro ® Ultima using mass transition 449.93284.8 atomic mass units for aripiprazole. Samples (190 L) were supplemented with d 3 -methadone as internal standard (1 mg/L in methanol) and extracted with 500 L of cold acetonitrile (Ϫ20°C); 100 L of supernatant was then directly injected into the HPLC-MS/MS instrument. Chromatographic separation of the analytes was performed on a reversed-phase C 18 column [Waters Sunfire ® ; 3.5-m particle size; 150 ϫ 2.1 mm (i.d.)] with a mobile phase consisting of acetonitrile, 1.5 mmol/L aqueous ammonium acetate, and formic acid (50:50:0.1 by volume) at a flow rate of 0.35 mL/min.
The automated HPLC method with column-switching enabled the analysis of serum samples containing aripiprazole and perphenazine, which had been added as internal standard, within Ͻ25 min (Fig. 1) . The on-line clean-up procedure efficiently removed matrix constituents. In samples supplemented with 50, 200, and 1000 g/L aripiprazole, the absolute recoveries for aripiprazole were 94.7%-111.5%, and the analytical recoveries were 96.7%-115.5%. To calculate assay precision, samples containing concentrations of 50, 250, and 400 g/L were analyzed. Mean (SD) measured concentrations were 50 (6), 253 (20), and 400 (39) g/L, respectively. Withinrun imprecision (as CV) was 9.1%, 8.1%, and 7.8%; between-day imprecision was 7.0%, 3.0%, and 4.7%; and between-run imprecision was 8.0%, 3.4%, and 4.8%, respectively. In accordance with the Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) guidelines (10 ), the limit of quantification was Ͻ50 g/L (see Fig.  1B ) because this is the lowest concentration at which the CV was Ͻ15% (10 ). When samples supplemented with 50 -1000 g/L aripiprazole were used, the method was linear with a correlation coefficient (r 2 ) Ͼ0.998. The equation for the linear regression line was: y ϭ 0.0026x ϩ 0.032 g/L. To test interference, drugs that might interfere with the measurement of aripiprazole were added to drug-free plasma. Among the 48 psychoactive drugs tested for interference (see Table 1 http://www.clinchem.org/content/vol51/issue9/), reboxetine, pipamperone, and norclozapine had retention times similar to that for aripiprazole.
For stability measurements, plasma supplemented with 500 g/L aripiprazole was stored for 14 days at room temperature in the dark or exposed to daylight. Concentrations were measured in duplicate on day 0 and reanalyzed on days 1, 3, 7, and 14. The results were as follows: 500 g/L on day 0, 503 g/L (101%) on day 1, 548 g/L (110%) on day 3, 495 g/L (99%) on day 7, and 485 g/L (97%) on day 14. Freezing and thawing did not lead to significant changes in drug concentrations.
Aripiprazole was found in measurable quantities in patient serum samples. HPLC fractions containing peaks that corresponded to aripiprazole were collected and analyzed by MS/MS to confirm the identity, using the mass transition 449.93284.8 atomic mass units for aripiprazole. Serum samples from 27 patients (12 male; age range, 19 -69 years) treated with daily doses of 10 -30 mg (mean, 18.4 mg/day; median, 15.0 mg/day) showed trough steady-state serum aripiprazole concentration variations among individual patients ranging from 105 to 549 g/L. The median aripiprazole concentration was 219 g/L, and the 25th and 75th percentiles were 146 and 254 g/L, respectively. In patient serum samples, an additional peak with a retention time of 16 min was observed (Fig. 1C) and was confirmed by MS/MS to be the active metabolite dehydroaripiprazole (4 ) . Quantification of the suggested metabolite, however, was not possible because reference material was not available.
The column-switching technique described here makes it possible to run the procedure automatically with minimal sample preparation before chromatographic analysis. The results of the assay validation met CLSI requirements (10 ) . Reboxetine (17.0 min), pipamperone (17.8 min), and the clozapine metabolite norclozapine (18.0 min) had retention times similar to that for aripiprazole (17.6 min) and thus interfered with aripiprazole measurements. These interferences should be taken into account when patients are treated with combinations of these drugs. In clinical practice, this TDM method revealed the expected interindividual variations in serum concentrations attributable to variations in patient compliance and variable metabolic capacities. The observed mean concentrations were similar to those reported in a pharmacokinetic study on healthy persons receiving steady-state doses of aripiprazole (5 ) . Target concentrations for optimal aripiprazole response, however, remain unclear. More studies are needed to define the therapeutic window of this novel antipsychotic drug. Future studies should also include analyses of the pharmacologically active metabolite because its contribution to clinical effects is unclear. Positron emission tomography imaging studies to quantify dopamine D2 receptor occupancy gave evidence that therapeutic doses of aripiprazole are associated with 90% dopamine receptor occupancy and blood concentrations of 100 -500 g/L (11 ). Our analyses of patients treated with therapeutic doses of aripiprazole revealed an interquartile range (25th-75th percentiles) of 
-254 g/L.
As long as more valid data are lacking, serum concentrations of 146 -254 g/L can be considered as a preliminary target range for TDM of aripiprazole. Moreover, it should be stressed that because pure and authentic reference materials for aripiprazole and its metabolite were not available, the accuracy of the method described here remains uncertain. The macrolide immunosuppressants sirolimus (Rapamycin; SRL) and its 40-O-(2-hydroxyethyl) derivative everolimus (Certican ® ; SDZ-RAD) are approved immunosuppressive agents for organ transplantation, but there is evidence that they can interfere with co-medications, including other immunosuppressive agents (1 ). SRL and SDZ-RAD are metabolized in humans by the hepatic and intestinal cytochrome P450 3A subfamily (2, 3 ) , which also metabolizes many other agents. Both have the same mechanism of action but differ in their half-lives and treatment regimes with co-medications. Because of their narrow therapeutic spectra, the clinical application of SRL and SDZ-RAD, like other immunosuppressants, is complicated by substantial intra-and interindividual variations in drug absorption, distribution, metabolism, and elimination (4 -6 ) . Their concentrations must be carefully monitored in posttransplantation regimens, and dosage adjustment to reduce the risk of toxicity and rejection depends on the analytical method used for monitoring (7) (8) (9) .
Simultaneous Measurement of Sirolimus and Everoli
Several HPLC methods with ultraviolet (UV) detection or mass spectrometry (MS) are available for measurement of SRL and SDZ-RAD individually (10 -16 ) , and liquid chromatography (LC) methods using MS or tandem MS allow simultaneous measurement of these compounds in combination with other immunosuppressants (17-22 ) . The purported advantage of LC-MS methods over LC-UV methods is the ability to monitor multiple drugs within the same analytical run. As the number of monitored compounds increases, however, instrument dwell time or the number of data points acquired for each mass transition may decrease and negatively affect the limit of quantification or precision (6, 23 ) . Furthermore, these methods are expensive and not readily available in most laboratories.
The presented reversed-phase HPLC-UV method for the simultaneous measurement of SRL and SDZ-RAD in whole blood was designed to allow easy sample preparation, to be simple to perform, to be cost-and timeeffective, and to have low limits of detection. Separation and quantification of 2 drugs in parallel are achieved by isocratic elution. Both drugs can be detected in a single run, which is a great advantage when transplant patients are switched from one drug to the other.
The SRL was kindly supplied by Wyeth-Ayerst Research (Princeton, NJ), the SDZ-RAD by Novartis Pharmaceuticals Corporation (Basel, Switzerland), and the internal standard (IS), ascomycin, by Sigma-Aldrich (Vienna, Austria). Stock solutions of each compound were prepared in methanol at concentrations of 1 mg/L for SRL and SDZ-RAD and 20 mg/L for ascomycin; all stock solutions were stored at Ϫ20°C. The solutions were stable at Ϫ70°C for at least 16 months. All analytical-or HPLCgrade reagents were purchased from Merck.
Calibrators and in-house control samples were prepared in separate drug-free human whole-blood stock solutions: 6 non-zero concentrations ( 
